Tkatch L S, Tweardy D J
Department of Medicine, University of Pittsburgh School of Medicine, PA 15213.
Lymphokine Cytokine Res. 1993 Dec;12(6):477-88.
In summary, both G-CSF and GM-CSF have been identified, cloned, and produced for pharmacologic use in humans. While both G-CSF and GM-CSF have had significant impact in the treatment of neutropenic states, G-CSF appears to be more advantageous than GM-CSF in overall efficacy and paucity of side effects. Much has been discovered about the structure of the G-CSF receptor but further work is necessary to determine its mechanism of signal transduction. As our understanding of G-CSF signaling advances, the therapeutic impact of our knowledge about G-CSF biology will evolve from the current focus on enhancing its effects in hematologic and oncologic illnesses to decreasing its effects in inflammatory conditions where overexhuberant neutrophil infiltration and activation cause disease.
总之，粒细胞集落刺激因子（G-CSF）和粒细胞-巨噬细胞集落刺激因子（GM-CSF）均已被鉴定、克隆并制备用于人类的药物治疗。虽然G-CSF和GM-CSF在中性粒细胞减少症的治疗中都产生了重大影响，但在总体疗效和副作用较少方面，G-CSF似乎比GM-CSF更具优势。关于G-CSF受体的结构已经有了很多发现，但仍需要进一步的研究来确定其信号转导机制。随着我们对G-CSF信号传导的理解不断深入，我们对G-CSF生物学知识的治疗影响将从目前专注于增强其在血液学和肿瘤疾病中的作用，转变为减少其在炎症性疾病中的作用，在这些疾病中，过度的中性粒细胞浸润和激活会导致疾病。
